Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Agonist muscle
16%
Ballistic
16%
Botulinum Neurotoxin (BoNT)
16%
Cardiovascular Reflexes
16%
Cervical Dystonia
21%
Cortical Excitability
16%
Diffusion-weighted Imaging
16%
Disease-causing mutations
16%
Dystonia
73%
Excitability
16%
G2019S
16%
Gene mutation
19%
Gene-gene Interaction
16%
Genetic Linkage Analysis
16%
Genetic Screen
23%
Genome-wide Association Data
16%
Imaging Studies
16%
Laryngeal Dystonia
21%
Leucine-rich Repeat Kinase 2 (LRRK2)
33%
Levodopa/carbidopa
16%
LOD Score
21%
Long-term Treatment
16%
Low Immunogenicity
16%
Meta-analysis
16%
Mouse Protection Assay
16%
Movement Disorders
22%
Multiplex
26%
Muscle Activity
16%
Myoclonus
16%
Myoclonus-dystonia
28%
Neural Correlates
16%
Neuropathology
16%
New Risks
16%
North America
16%
Parkin mutation
16%
Parkinson
16%
Parkinson Patients
16%
Parkinson's Disease
100%
Primary Dystonia
21%
R1441C
16%
Risk Loci
16%
Sarcoglycan
16%
Sensory Discrimination
16%
Substantia Nigra
16%
Susceptibility Genes
16%
Task-specific Dystonia
16%
Tremor
16%
Voxel-based Morphometry
16%
Wilson Disease
16%
Wrist Movement
16%
Neuroscience
Agonist
8%
Carbidopa/Levodopa
12%
Cardiovascular Physiology
8%
Cardiovascular Reflex
16%
Central Nervous System
16%
Cerebellum
8%
Chromosome 2
9%
Diffusion MRI
16%
Dystonia
67%
Excitability
16%
Familial Parkinson's Disease
8%
Gene Interaction
16%
Gene Mutation
16%
Gray Matter
7%
Myoclonus
28%
Parkin
22%
Parkinson's Disease
84%
Primary Motor Cortex
5%
Putamen
6%
Sarcoglycan
16%
Sensorimotor Cortex
6%
Spasmodic dysphonia
18%
Stereotypic Movement Disorder
7%
Substantia nigra
12%
Voxel-Based Morphometry
16%
X Chromosome
8%
